A refractory heterogeneous Cryopyrin-Associated Periodic Syndrome (CAPS) phenotype related to V198M mutation responds to canakinumab - a case report

Conclusion Based on our experience in this patient and a review of literature on efficacy of IL-1 inhibition in CAPS patients with V198M mutation, high dose canakinumab i.v* with increased dosing frequency yields symptomatic relief without evidence of increased AE.

Saved in:
Bibliographic Details
Published in:Pediatric Rheumatology 2011-09, Vol.9 (S1), p.P9-P9, Article P9
Main Authors: Hansmann, Sandra, Zimmer, Christiane, Moll, Monika, Rieber, Nikolaus, Kuemmerle-Deschner, Jasmin B
Format: Article
Language:English
Subjects:
Genotype & phenotype
Infections
Mutation
Pediatrics
Poster Presentation
Rheumatology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Conclusion Based on our experience in this patient and a review of literature on efficacy of IL-1 inhibition in CAPS patients with V198M mutation, high dose canakinumab i.v* with increased dosing frequency yields symptomatic relief without evidence of increased AE.
ISSN:1546-0096
1546-0096
DOI:10.1186/1546-0096-9-S1-P9